The overall goal of my present and future research consists of developing more effective strategies to treat limb and myocardial ischaemia. My research also addresses diabetes-related microvascular complications, in particular impaired angiogenesis and wound healing. To achieve these aims, our group is applying state of the art concepts in the new field of therapeutic angiogenesis, which postulates that local delivery of growth factors that can promote clinically valuable increase in blood flow. Such growth factors are either delivered as proteins or as gene therapy. My own contribution has been the identification of novel angiogenic factors, in particular human tissue kallikrein and nerve growth factor, and developing platforms for translational research to bring these discoveries from the bench to the bedside. More recently, the idea has emerged that therapeutic angiogenesis can also be achieved using stem cell transplantation. We are currently engaged in studies aimed at challenging the therapeutic potentiality of human stem cells (embryonic, foetal, and adult) for the regeneration of wounded tissues in murine models of myocardial infarction and ischaemic diabetic wounds. In particular, we have funded plans to bring human pericytes to a first in man clinical trial by 2015.
A recent biography is available in the AHA Journal Circulation "European perspectives" at the URL http://circ.ahajournals.org/content/126/7/f37.full.pdf?ijkey=QdK5BJZZAQMZzVQ&keytype=ref
Prof. P. Madeddu, is Chair of Experimental Cardiovascular Medicine and Head of the Section of Regenerative Medicine, School of Medicine, University of Bristol, where he relocated in 2005. He was previously Associate Professor at the Medical University of Sassari and Head of Gene Therapy Department at the Inter-University Consortium of Biosystems and Biostructures, Porto Conte Technological Park, Italy. He is Associate Editor for Circulation Research, ATVB, Pharmacology &Therapeutics and Regenerative Medicine. Previously, he was Associate Editor for the British Journal of Pharmacology.
Prof. Madeddu is recipient of several current and past grants on therapeutic angiogenesis, vasculogenesis and systems biology of bone marrow, funded by U.K., European and international organizations, including the Medical Research Council (MRC), the British Heart Foundation (BHF), the Wellcome Trust, the European Association of the Study of Diabetes (EASD), the Juvenile Diabetes Research Foundation (JDRF). He was and is a partner in the European FP6- and FP7-supported frameworks “EVGN” and “RESOLVE”.
Prof. Madeddu’s main interest is to develop new mechanistic therapies for the cure cardiovascular disease. He has 188 peer-reviewed publications in PubMed. His main contribution consists in the characterization of the role of kallikrein-kinin system in angiogenesis and vascular biology and of mechanisms implicated in the pathogenesis of diabetic microangiopathy. He discovered that a form of microangiopathy affecting the bone marrow of diabetic models and diabetic patients impairs stem cell homeostasis He also contributed in initial studies that led to the recognition of nerve growth factor as an angiogenic agent, a field that was then fully developed by Prof. Emanueli.
Prof. Madeddu is engaged in many protocols of angiogenesis gene therapy and cell therapy. His team set up a method for isolation and expansion of human pericyte progenitor cells. These cells showed a remarkable regenerative potential in model of ischemia and represent a valuable means for study the role of vascular supportive cells in different vascular pathologies.
View complete publications list in the University of Bristol publications system
Professor Madeddu currently teaches 1 courses:
Edit this profile If you are Professor Paolo Madeddu, you can edit this page. Login required.